UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 31, 2008
 
BIO-BRIDGE SCIENCE, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
000-51497
20-1802936
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
1211 West 22nd Street, Suite 615, Oak Brook, Illinois
60523
(Address of principal executive offices)
 
(Zip Code)
Registrant’s telephone number, including area code: 630-928-0869
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
This Form 8-K and other reports filed by the Registrant from time to time with the Securities and Exchange Commission (collectively the “Filings”) contain forward looking statements and information that are based upon beliefs of, and information currently available to, the Registrant’s management as well as estimates and assumptions made by the Registrant’s management. When used in the Filings the words “anticipate”, “believe”, “estimate”, “expect”, “future”, “intend”, “plan” or the negative of these terms and similar expressions as they relate to the Registrant or the Registrant’s management identify forward looking statements. Such statements reflect the current view of the Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Registrant’s industry, operations and results of operations and any businesses that may be acquired by the Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
 
ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.
 
As used in this report, "we", "us", "our" or "BGES" refer to Bio-Bridge Science, Inc., a Delaware corporation and its subsidiaries.
 
As previously reported under Item 2.01 of the Current Report on Form 8-K filed by us with the Securities and Exchange Commission on July 31,2008, Bio-Bridge Science (HK) Co., Ltd., a wholly-owned subsidiary of Bio-Bridge Science, Inc. entered into an equity sale and purchase agreement with Huhhot Xinheng Baide Biotechnology Co. Ltd., (the “ Seller” or “Xinheng Baide”), a serum manufacturing and distribution company organized under the laws of the People's Republic of China, pursuant to which we agreed to purchase newly issued shares of Seller. The acquisition was consummated as of July 31, 2008 pursuant to the terms of the equity sale and purchase agreement. The description of the acquisition included in the July 31 is incorporated by reference herein.
 
This Current Report on Form 8-K/A provides the historical financial statements of the business acquired under Item 9.01(a) and the pro forma financial information under Item 9.01(b), which financial statements and information were not included in the July 31 Form 8-K.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(a) FINANCIAL STATEMENTS OF BUSINESS ACQUIRED. Huhhot Xinheng Baide Biotechnology Co.Ltd. audited Financial Statements as of and for the years ended December 31, 2007 and 2006 and unaudited condensed financial statements as of March 31, 2008 and for the three months ended March 31, 2008 and 2007 are filed as Exhibit 99.1 to this amendment and incorporated herein by reference.

(b) PRO FORMA FINANCIAL INFORMATION. The pro forma financial information with respect to the transaction described in Item 2.01 is filed as Exhibit 99.2 to this amendment and incorporated herein by reference.
 
Exhibit Number
 
Description
     
  99.1
 
Financial Statements of business acquired
     
99.2
 
Unaudited pro forma financial information
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
 
BIO-BRIDGE SCIENCE, INC.
 
  		 
  		 
 
Date:  August 12, 2008 By:  
/s/ Liang Qiao, MD.
 
Name  
Liang Qiao, MD.
 
Title:   
Chief Executive Officer
 
 
 
Bio Bridge Science (CE) (USOTC:BGES)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024 Haga Click aquí para más Gráficas Bio Bridge Science (CE).
Bio Bridge Science (CE) (USOTC:BGES)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024 Haga Click aquí para más Gráficas Bio Bridge Science (CE).